<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interlukin-2 (IL-2) is an important cytokine in the brain: IL-2 and its receptors are involved with inflammatory processes </plain></SENT>
<SENT sid="1" pm="."><plain>Chronological changes in IL-2 level in serum, and IL-2 and its receptor (IL-2 receptor beta, IL-2Rbeta) immunoreactivities and levels were examined in the hippocampal CA1 region after transient forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in gerbils </plain></SENT>
<SENT sid="2" pm="."><plain>IL-2 level in serum significantly decreased 12 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>IL-2 immunoreactivity was detected in the somata of pyramidal cells in sham-operated group </plain></SENT>
<SENT sid="4" pm="."><plain>At 15 min after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, IL-2 immunoreactivity was shown in non-pyramidal cells as well as pyramidal cells </plain></SENT>
<SENT sid="5" pm="."><plain>One day after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, IL-2 immunoreactivity was lowest, and IL-2 immunoreactivity is shown in non-pyramidal cells from 2 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Four days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, IL-2 immunoreactivity was shown in dying pyramidal cells </plain></SENT>
<SENT sid="7" pm="."><plain>IL-2Rbeta immunoreactivity in the sham-operated and 15 min-3 min post-ischemic groups is detected in the cell membrane of pyramidal cells </plain></SENT>
<SENT sid="8" pm="."><plain>From 3 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, IL-2Rbeta immunoreactivity is found in cytoplasm and nuclei, but not in cell membrane </plain></SENT>
<SENT sid="9" pm="."><plain>IL-2Rbeta immunoreactivity decreases from 6 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and is shown mainly in non-pyramidal cells from 3 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>The data of Western blot analyses for IL-2 and IL-2Rbeta was similar to the immunohistochemical data </plain></SENT>
<SENT sid="11" pm="."><plain>IL-2 infusion into cerebrospinal fluid did not protect hippocampal neurons from ischemic damage </plain></SENT>
<SENT sid="12" pm="."><plain>These results suggest that IL-2 and IL-2Rbeta show malfunction from 3 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and exogenous IL-2 does not protect ischemic neuronal damage </plain></SENT>
</text></document>